Emmetrope, Inc
0 likes511 views
Emmetrope Inc. is developing a line of accommodating intraocular lenses (IOLs) called ActaLens, ActaLens-Duo, and ActaLens-SC. The ActaLens models use a restrained hinge mechanism to allow movement of the optic when the eye focuses. Early clinical studies show the ActaLens providing over 0.5mm of movement and an estimated 0.5 diopters of accommodation. The dual optic ActaLens-Duo and shape changing ActaLens-SC are expected to provide even greater accommodation.
Emmetrope, Inc
- 1. EMMETROPE Emmetrope Inc. • Developing a line of accommodating IOLs • Broad coverage of restrained lens technology – Single optic: ActaLensTM, • Clinical Study Phase, podium presentation at ESCRS 2014 – Dual Optic: ActaLens-Duo – Shape Change Optic: ActaLens-SC La Canada, CA Andrew Phillips, M.D. President & CEO 3 Versions, same platform:
- 2. EMMETROPE ACTIVATED: RESTRAINT RELEASED1 MONTH CYCLOPLEGIA YAG MANUFACTURED RESTRAINED IMPLANTED MECHANISM
- 3. EMMETROPE Total Axial Displacement, 10 Months Post-Implant UBM (Cyclo-Pilo) -0.4 -0.2 0 0.2 0.4 0.6 0.8 MM CrystaLensActaLens CrystaLens® -.07 + .07 MM ActaLens® +.48 +.09 MM
- 4. EMMETROPE ActaLens Movement Pentcam HR Total Movement, 1 year -0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 MM ActaLensCrystaLens ActaLens 0.37 + .10 CrystaLens 0.05 + .06
- 5. EMMETROPE UBM of ActaLens at 10 Months Cyclopentalate 1% Pilocarpine 2% Total axial movement 0.52 MM REICHERT UBM 35MhZ 16 ° Patient AV, male, 68 y/o, UCVA 20/20-2 31 °
- 6. EMMETROPE Estimated Accommodative Effect of Actalens: ~ .5D axial shift alone may not be sufficient as lens flexes from observed 10 to 24 degrees 10 degrees (Cyclopentalate) 24 degrees (Pilocarpine)
- 7. EMMETROPE ActaLens-SC ( Shape-Change) • Same platform and hinge design as fixed optic version – Again, .4 MM movement and 10 to 15 degrees flexion expected • 2 layer lens. Base layer firmer silicone. Top layer of softer silicone deforms over base layer as haptics flex.
- 8. EMMETROPE ActaLens vs ActaLens-SC Change in optical power for flexion of haptics from 10 to 24 degrees Fixed-optic design: ~ .5D Dual-layer shape change: 4D +
- 10. EMMETROPE Summary • ActaLens – UBM, Pentacam, and Lenstar proven movement – Novel, capsule-independent mechanism • Actalens-Duo: Dual optic design – Increases accommodative effect • Actalens-SC – Using same clinically tested platform from first generation Actalens, > 5 D total pharmacological accommodation expected, lens power independent. – Objectively measurable accommodation greater than 2 D will be crucial to success.
- 11. EMMETROPE Evaluation of Movement at 20 Months • Independent analysis – VIROS, N. Hirnshall MD, PhD, Findl, O, MD • Lenstar PCI measurement of cyclo/pilo axial shift at 20 months confirms movement: • .46 MM + .13 total movement of ActaLens • no axial shift in control group
- 12. EMMETROPE Emmetrope Inc. • Developing a line of accommodating IOLs • Broad coverage of restrained lens technology – Single optic: ActaLensTM, • Clinical Study Phase, podium presentation at ESCRS 2014 – Dual Optic: ActaLens-Duo – Shape Change Optic: ActaLens-SC La Canada, CA Andrew Phillips, M.D. President & CEO 3 Versions, same platform: